Satellos Bioscience Inc.
Ryan Mitchell is currently serving as Vice President of Corporate Development, Vice President of Business Development, and has previously held various roles in business development. Prior to their current position, Ryan worked as a Contract Scientific Consultant at Bloom Burton & Co. and as a Group Leader at McMaster University's Stem Cell and Cancer Research Institute. Ryan holds a Ph.D. in Biochemistry and Biomedical Science from McMaster University, where Ryan also obtained their Bachelor's Degree. Ryan is actively involved in leading a cellular reprogramming work group and conducting mechanism of action studies on novel small molecules with selective anti-cancer activity.
This person is not in any teams
Satellos Bioscience Inc.
Satellos is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Satellos was founded on the discovery that dysregulated muscle stem-cell polarity - a process that balances replenishment of muscle stem cells and production of specialized tissue cells- can lead to the inability of the body to properly repair and regenerate muscle throughout life. Satellos' lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. Accordingly, Satellos applies its proprietary discovery platform, MyoReGenX, to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated.